Back to search results

Scrambler Therapy for Chronic Pancreatitis Pain

This study is testing a treatment called Scrambler Therapy for adults who have ongoing abdominal pain from chronic pancreatitis that hasn't improved with other treatments. Scrambler Therapy is a non-invasive (no surgery) device that uses electrodes placed on your skin to send "non-pain" electrical signals. The goal is to help your brain change how it senses pain. About 40 adults will participate. You would receive 5-10 treatment sessions, and researchers will follow up for 3 months to see how your pain and quality of life change. This study aims to gather initial information to help plan larger studies in the future.

Study design
This is a single-arm study, meaning all participants receive the same treatment. It plans to enroll about 40 adults.
What's involved
You would have 5-10 daily Scrambler Therapy sessions, each lasting 30-40 minutes. You would also have weekly pain ratings collected and complete questionnaires at 3 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07174609

Scrambler Therapy in Chronic Pancreatitis

Recruiting
NAAges 18+InterventionalTreatment
Johns Hopkins University
~40 participants
Updated 2025-09-16 on ClinicalTrials.gov
What's tested:Scrambler Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility as assessed by enrollment rate
Measured over During recruitment ( expected 24 months)
+3 more outcomes measured

Conditions

Chronic Pain
Pancreatitis
Chronic Pancreatitis

Explore related trials

Chronic Pancreatitis

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Mahya Faghih · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Mahya Faghih
[email protected]
443-287-4680
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 years and older
Diagnosis of chronic pancreatitis with refractory abdominal pain
Able to provide written informed consent in English
Sufficient English language ability to complete study questionnaires
Reliable and regular access to a phone for follow-up

Exclusion

Unable or unwilling to provide written consent
History or presence of a significant medical or psychiatric condition that would interfere with study participation
Pregnant or lactating women
Coronary stents or implanted metallic/electrical devices (pacemaker, defibrillator, aneurysm clips)
History of epilepsy, traumatic brain injury, or myocardial infarction within the past 6 months
Skin conditions preventing electrode placement (e.g., open wounds)
Any condition that, in the investigator's opinion, places the participant at increased risk or prevents full compliance with study procedures

What this trial measures

  • Feasibility as assessed by enrollment rateDuring recruitment ( expected 24 months)

    Number of eligible patients who consent and enroll divided by the total number of eligible patients approached.

  • Feasibility as assessed by treatment adherenceDuring treatment period (up to 2 weeks)

    Number of participants who complete a minimum of 5 Scrambler Therapy sessions out of the planned 5-10, or who discontinue earlier due to achieving adequate pain relief.

  • Feasibility as assessed by treatment adherence rateDuring treatment period (average 5-10 days, up to 2 weeks)

    Proportion of participants who complete a minimum of 5 Scrambler Therapy sessions out of the planned 5-10, or who discontinue earlier due to achieving adequate pain relief.

  • Feasibility as assessed by retentionBaseline through 3 months post-treatment

    Proportion of enrolled participants who complete the 3-month follow-up assessments, including pain ratings.